Renal Cancer Therapeutics: Now What? Cancer Network By Walter M. Stadler, MD, FACP 1 | March 13, 2012 The development of vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors for the treatment of renal cancer is a real success story. |
